BC Week In Review | Jan 11, 2019
Clinical News

Aevi's AEVI-001 misses in Phase II for children with ADHD

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) said AEVI-001 missed the primary endpoint in both Parts A and B of the Phase II ASCEND trial to treat ADHD in patients ages 6-17. The company plans to conduct...
BioCentury | Apr 7, 2017

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Apr 7, 2017

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Mar 23, 2017
Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
BC Extra | Mar 20, 2017
Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
BC Week In Review | Feb 1, 2017
Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
BioCentury | Oct 3, 2016

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Jun 27, 2016
Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
BC Week In Review | Oct 5, 2015
Company News

neuroFix Therapeutics, Medgenics deal

Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix is eligible to receive $6 million in cash and stock upon the earlier of the completion of an...
Items per page:
1 - 9 of 9